Scarica l'app Stockscreener
7.52
2.59%
-0.20
Dopo l'orario di chiusura:
7.46
-0.06
-0.80%
Arvinas Inc Borsa (ARVN) Ultime notizie
Acadian Asset Management LLC Takes $1.12 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Arvinas (NASDAQ:ARVN) Board of Directors Initiates Stock Repurchase Plan - MarketBeat
H.C. Wainwright reiterates Buy rating on Arvinas stock, maintains $18 target - Investing.com Canada
Portfolio Update: How do insiders feel about TNHLPJobs Report & Fast Momentum Stock Entry Tips - khodrobank.com
Arvinas (NASDAQ:ARVN) Earns Neutral Rating from Wedbush - MarketBeat
Arvinas reboots, cuts more staff; Porges joins Lazard - BioPharma Dive
Market Trends: Can CVR Energy Inc. navigate macro headwinds2025 Market WrapUp & Weekly Setup with ROI Potential - khodrobank.com
New Highs: Can Arvinas Inc outperform in the next rallyJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - khodrobank.com
BTIG Research Cuts Arvinas (NASDAQ:ARVN) Price Target to $10.00 - MarketBeat
Is WM Technology Inc. currently under institutional pressureJuly 2025 Rallies & Risk Controlled Stock Alerts - khodrobank.com
Stephens Lowers Arvinas (NASDAQ:ARVN) Price Target to $14.00 - MarketBeat
Arvinas (NASDAQ:ARVN) Raised to Strong-Buy at Barclays - MarketBeat
Arvinas stock price target lowered to $15 at Barclays on licensing plans - Investing.com
New Highs: What dividend growth rate does Arvinas Inc offer2025 Growth vs Value & Community Driven Trade Alerts - khodrobank.com
Returns Recap: Can Arvinas Inc reach all time highs this yearTake Profit & Step-by-Step Swing Trade Plans - khodrobank.com
Arvinas Holding Company: Strategic Shifts and Growth Opportunities Drive Buy Rating - TipRanks
Arvinas stock price target lowered to $14 at Stephens on Pfizer partnership update - Investing.com Canada
Amid investor pressures, Arvinas to cut 15% of staff as it reshapes drug strategy with Pfizer - Hartford Business Journal
BTIG Maintains Buy Rating on Arvinas (ARVN) Despite Lowered Pric - GuruFocus
Pfizer, Arvinas to sell rights to lead PROTAC one month after filing for FDA review - Endpoints News
Arvinas amends collaboration with Pfizer - The Pharma Letter
Arvinas stock rises as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com Canada
Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside - insights.citeline.com
ARVN: Stephens & Co. Lowers Price Target, Maintains Overweight R - GuruFocus
Arvinas stock rises as Cantor Fitzgerald reaffirms Overweight rating - Investing.com
Arvinas (NASDAQ:ARVN) Now Covered by Analysts at Barclays - MarketBeat
Arvinas stock price target lowered to $14 at Stephens on Pfizer partnership update By Investing.com - Investing.com Australia
Pharma News: Should I trade or invest in Arvinas IncJuly 2025 PostEarnings & High Win Rate Trade Tips - خودرو بانک
Wedbush Cuts Price Target on Arvinas to $9 From $10, Keeps Neutral Rating - MarketScreener
Arvinas and Pfizer to out-license breast cancer drug vepdegestrant By Investing.com - Investing.com Australia
Market Catalysts: Is Surf Air Mobility Inc impacted by rising ratesJuly 2025 Momentum & AI Forecasted Stock Moves - khodrobank.com
Arvinas (ARVN) Announces $100M Share Buyback Plan - GuruFocus
Arvinas announces $100M share repurchase program - MSN
Oppenheimer Maintains Arvinas(ARVN.US) With Hold Rating - 富途牛牛
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - The Mighty 790 KFGO
Arvinas (ARVN) and Pfizer Shift Commercialization Strategy for C - GuruFocus
Arvinas (ARVN) Refocuses Strategy and Optimizes Costs After Stra - GuruFocus
Pfizer (PFE) and Arvinas Seek Partner for Vepdegestrant's Commer - GuruFocus
Arvinas expects $4.5 million costs for workforce reductionSEC filing - MarketScreener
Arvinas provides update on collaboration with Pfizer - MarketScreener
Arvinas and Pfizer to out-license breast cancer drug vepdegestrant - Investing.com
Arvinas Announces 15% Workforce Reduction and Cost Savings - TipRanks
Arvinas, Pfizer to outlicense commercialization of cancer asset vepdegestrant - Seeking Alpha
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - GlobeNewswire
Arvinas, Inc. and Pfizer Jointly Agreed to Out-License the Commercialization Rights to Vepdegestrant to Third Party - MarketScreener
$100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback - Stock Titan
Update Recap: Can Arvinas Inc expand into new marketsJuly 2025 Macro Moves & Daily Stock Momentum Reports - خودرو بانک
ARVN: Barclays Initiates Coverage with Overweight Rating and $16 PT | ARVN Stock News - GuruFocus
Barclays initiates coverage on Arvinas stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Arvinas stock with Overweight rating - Investing.com
Market Review: Is Arvinas Inc forming a double bottom2025 Geopolitical Influence & Reliable Price Breakout Alerts - خودرو بانک
Market Catalysts: Will Arvinas Inc. stock recover after earnings2025 Geopolitical Influence & Verified Trade Idea Suggestions - khodrobank.com
Aug Drivers: Does SuperCom Ltd. have strong EBITDA marginsFed Meeting & Long Hold Capital Preservation Tips - خودرو بانک
Earnings Miss: What’s the profit margin of OXLCPWeekly Profit Recap & AI Enhanced Trading Signals - خودرو بانک
Can Arvinas Inc reach all time highs this year2025 Sector Review & Safe Capital Growth Trade Ideas - خودرو بانک
Risk Off: What are Arvinas Incs earnings expectationsJuly 2025 Macro Moves & Entry Point Confirmation Alerts - خودرو بانک
1.43%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):